North East and North Cumbria
ICS Formulary
ICS Formulary
8 Malignant disease and immunosuppression
08-02-01 Antiproliferative immunosuppressants
| Azathioprine |
|
Formulary
|
|
 North of Tyne, Gateshead and North Cumbria - Azathioprine Shared Care Agreement (Renal Transplant in adults) South Tyneside & Sunderland APC Shared Care Guideline - Azathioprine in Neurology |
|
unlicensed) is also available.| Mycophenolate Sodium Myfortic® |
|
Formulary
|
|
|
MHRA Drug Safety Updates - Mycophenolate |
|
|
Links
- Cancer Drug Fund List
- MHRA Drug Safety Updates - Mycophenolate
- MHRA Drug Safety Updates - Mycophenolate
- NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
- NICE TA481: Immunosuppressive therapy for kidney transplant in adults
- NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
- NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
- NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
- North of Tyne, Gateshead and North Cumbria - Azathioprine Shared Care Agreement (Renal Transplant in adults)
- Northern Cancer Alliance
- Northern England Clinical Networks Palliative and End of Life Care Guidelines
- South Tyneside & Sunderland APC Shared Care Guideline - Azathioprine in Neurology
- South Tyneside & Sunderland APC Shared Care Guideline - Mycophenolate in Neurology